

MARCH 2018

Half-year result presentation



CFO JENNI PILCHER

Disclaimer

Summary of information: This presentation contains general and background information about Mach7 Technologies Limited (“M7T”) activities current as at the date of the presentation and should not be considered to be comprehensive or to comprise all the information that an investor should consider when making an investment decision. This presentation is not a prospectus, disclosure document, product disclosure statement or other offering document under Australian law or under any other law. The presentation does not purport to contain all the information that a prospective investor may require in assessing a possible investment in M7T nor does it contain all the information which would be required in a prospectus prepared in accordance with the requirements of the Corporations Act 2001 (Cth). The information provided is in summary form, has not been independently verified, and should not be considered to be comprehensive or complete. It should be read solely in conjunction with the oral briefing provided by M7T and all other documents provided to you by M7T. The information in this presentation remains subject to change without notice. M7T is not responsible for providing updated information and assumes no responsibility to do so.

Not financial product advice: This financial information provided in this presentation is for information purposes only. The information contained in this presentation is of a general nature only and is not a financial product, investment advice or a recommendation to acquire M7T securities and has been prepared without taking into account the objectives, financial situation or needs of any person or entity. Before making an investment decision prospective investors should consider the appropriateness of the information having regard to their own objectives, financial situation and needs, and seek legal, taxation and financial advice appropriate to their jurisdiction and circumstances. M7T is not licensed to provide financial product advice in respect of its securities or and other financial products. Cooling off rights do not apply to the acquisition of M7T securities. M7T assumes that the recipient is capable of making its own independent assessment, without reliance on this document, of the information and potential investment and will conduct its own investigation.

Disclaimer: M7T and its related bodies corporate and each of their respective directors, agents, officers, employees and advisors expressly disclaim, to the maximum extent permitted by the law, all abilities (however, caused, including negligence) in respect of, make no representations regarding, and take no responsibility for, any part of this presentation and make no representation or warranty as to the currency, accuracy, reliability or completeness of any information, statements, opinions, conclusions or representations contained in this presentation. In particular, this presentation does not constitute, and shall not be relied upon as, a promise, representation, warranty or guarantee as to the past, present or future performance of M7T.

Future performance: This presentation contains certain forward-looking statements and opinions. The forward-looking statements, opinions and estimates provided in this presentation are based on assumptions and contingencies which are subject to change without notice, as are statements about market and industry trends, which are based on interpretations of current market conditions. Forward-looking statements, including projections, forecasts and estimates, are provided as a general guide only and should not be relied on as an indication or guarantee of future performance and involve known and unknown risks, uncertainties and other factors, many of which are outside the control of M7T. Past performance is not necessarily a guide to future performance and no representation or warranty is made as to the likelihood of achievement or reasonableness of any forward looking statements or other forecast.

Risks: An investment in M7T securities is subject to investment and other known and unknown risks, some of which are beyond the control of M7T. You should have regard to the ‘Key Risks’ section of this presentation which outlines some of these risks.

Not an offer: This presentation is not, and should not be considered as, an offer or an invitation to acquire securities in M7T or any other financial products and neither this document nor any of its contents will form the basis of any contract or commitment. This presentation is not a prospectus. Offers of securities in M7T will only be made in places which, or to persons to whom it would be lawful to make such offers. This presentation must not be disclosed to any other party and does not carry any right of publication. Neither this presentation nor any of its contents may be reproduced or used for any other purpose without the prior written consent of M7T.

No distribution in the US: This presentation is not an offer of securities for sale in the United States. Any securities to be issued by M7T have not been and will not be registered under the US Securities Act of 1933, as amended (the “US Securities Act”) and may not be offered or sold in the United States absent registration or an exemption from registration under the US Securities Act. No public offer of the securities is being made in the United States and the information contained herein does not constitute an offer of securities for sale in the United States. This presentation is not for distribution directly or indirectly in or into the United States or to US persons.

Monetary values: Unless otherwise stated, all dollar values are in Australian dollars (AUD\$). The information in this presentation remains subject to change without notice.

Sophisticated and professional investor: By attending this presentation, you present and warrant that (i) if you are in Australia, you are a person to whom an offer of securities may be made without a disclosure document as defined in the Corporation Act 2001 (Cth) (“Corporation Act”) on the basis that you are exempt from the disclosure requirements of Part 6D.2 in accordance with Section 708(8) or 708(11) of the Corporations Act; (ii) if you are in the United States, you are a qualified institutional buyer (as defined under Rule 144A Under the U.S. Securities Act; (iii) if you are outside Australia and the United States, you are a person to whom an offer and issue of securities can be made outside Australia without registration, lodgement or approval of a formal disclosure document or other filing in accordance with the laws of that foreign jurisdiction. If you are not such a person, you are not entitled to attend this presentation. Please return this presentation and any copies and do not provide this presentation to any other person.


No distribution: Distribution of this presentation may be restricted by law. Persons who come into possession of this presentation should seek advice on and observe any such restrictions. Any failure to comply with such restrictions may constitute a violation of applicable security laws.

POSITIVE MOMENTUM CONTINUES


New sales	<p>Sales orders \$\$ received this half outperformed the last five halves, and included:</p> <ul style="list-style-type: none">• University of Vermont Medical Centre (new customer)• Sentara data migration project (existing customer)
New markets	<ul style="list-style-type: none">• First sales into Vietnam and The Netherlands• Distributors signed up in Mexico, Panama & Ecuador
New partners	<ul style="list-style-type: none">• Zebra Medical Vision (medical imaging and artificial intelligence)• sirenMD (real-time care coordination telehealth communication)
New products	<ul style="list-style-type: none">• Sage healthcare data services platform
Strengthened balance sheet	<ul style="list-style-type: none">• Positive operating cash flow in H1• Raised \$2m of capital, cash on hand \$4.9m at 31 December 2017
Increasing ARR	<ul style="list-style-type: none">• Annual recurring revenue (ARR) increased +24% over prior corresponding period

IMPROVING FINANCIAL TRENDS


ARR By Region (USD)
4 YEAR CAGR +66%



Revenue and Cash (USD)



EBITDA Losses (USD)



HALF YEAR RESULT

P&L	HY 2018 A\$m	HY 2017 A\$m	% Change
Revenue	3.9	4.8	(19%)
Operating expenditure	(5.5)	(6.7)	(18%)
Other income/expenses (net)	0.0	0.6	(97%)
EBITDA (adjusted)	(1.6)	(1.3)	27%
Share-based payments expense	(0.4)	(0.1)	561%
Interest expense	(0.0)	(0.2)	(95%)
Depreciation, amortization and related tax credit (non-cash)	(1.4)	(2.3)	(44%)
Loss for the half-year	(3.4)	(3.9)	(14%)

POSITIVES:-

- ✓ Annual recurring revenue +24%
- ✓ Operating expenses down 18%
- ✓ Interest ~nil due to no debt
- ✓ Loss improved by 14%

NOTE:-

- Revenue down due to one-off revenue contract in Middle-East in PCP – however orders were up which means future revenue

HALF YEAR RESULT

BALANCE SHEET	HY 2018 A\$m	FY 2017 A\$m	% Change
Cash	4.9	2.8	+67%
Net assets	3.8	3.4	+10%
Deferred revenue	3.6	2.9	+27%
Debt	(0.0)	(0.0)	-

POSITIVES:-

- ✓ Cash improved 67%
- ✓ Deferred revenue up 27%
 - more deals signed
 - increased revenue in future periods
- ✓ Net assets improved
- ✓ No debt

FINANCIAL UPDATE

FINANCIAL INFORMATION (\$A)

Share price (close 5-Mar-18)	\$0.295
Number of shares (m) ^{1,2}	130.0m
Market Capitalisation	\$38.8m
Cash on Hand (31/12/17)	\$4.9m
Debt	\$-
Enterprise Value	\$33.9m

1. Excludes 5.9m unlisted options

2. Excludes 6.8m unlisted performance rights

OWNERSHIP STRUCTURE

1. JM Financial Group (Melbourne) – 10.8%
2. Oceania Capital Partners (Sydney) – 9.5%
3. BV Healthcare (Singapore) – 8.7%
4. Founder, CSO (Singapore) – 4.4%
5. PT Dwi Satrya Utama (Indonesia) – 3.7%

Top 5 = 37.0%

Top 10 = 51.9%

Top 20 = 69.5%

MACH7 EVOLUTION




2007
Mach7 Founded



2010
First Pilots Deployed
Cloud Deployments
USA & Middle East



2012
First Commercial wins
Revenue phase begins



2016
Merger with 3DM:ASX



2017
New commercial strategy

Specialty Applications: v8

Enterprise Imaging Platform: v11

Data Services Platform: v12

sage

CUSTOMER EVOLUTION

Mach7's global customer base is progressing from earlier adopters towards significantly larger mid-market




Early customers – academic medical centres and large integrated delivery networks


Mid-market opportunities – mid-market adoption of VNA technology increasingly dominating Mach7's customer focus

Recognition

2016 IDC MarketScape Report
Recognizes Mach7 Highest
Overall in Capabilities and
Strategies



DATA SERVICES HEALTHCARE PLATFORM



Intelligent clinical Framework



Diagnostics

- Sage PACS
- Universal Worklist
- QC Workflow
- DMWL
- Traditional PACS Connectors

Enterprise Imaging

- VNA
- Enterprise Viewing
- Image Distribution and Routing
- Pre and Post Fetching
- HL7 Interface Engine

Clinical

- EMR Data Connectors
- EMR Interoperability Enablement
- EMR Image Enablement
- Clinical Portal
- Referring Portal
- Image Upload & Sharing
- Visual Light Data Capture

Patient

- Patient Portal
- Care Coordination

Analytics

- Sage AI
- Machine Learning
- Descriptive and Predictive Analytics
- 3rd Party AI Connectors
- Prepare data for AI (de-identify)

Specialties

- Radiology
- Cardiology
- Dermatology
- Ophthalmology
- Orthopedics
- Wound Care
- Sports Medicine
- ...

SYSTEM MONITOR

- Proactive Alerting
- System Health Monitoring
- Self Healing
- Auto Resolve

COMMUNICATIONS

- DICOM
- DICOM Web
- HL7
- FHIR
- XDS
- Web Services

DATA MANAGEMENT

- Storage Management
- Data Lifecycle
- Localization
- Hierarchical Storage
- Data Process Plug-in Framework

SECURITY

- Role Based Access
- App Access Controls
- OWASP Compliant
- Encryption
- Detailed Audit Record
- Break Glass

BUSINESS CONTINUITY

- Highly Available
- Auto Failover
- Zero Downtime Update Capable
- Auto Load Balancing
- Plug-in Scalability

Meet Sage

A platform that enables access, interoperability, and liquidity to your clinical data. A Data Services Platform (DSP).

#WORKSMART with Sage by



Reduce vendor contracts and service agreement costs by over 30%

Replaced 3 applications and annual service agreements with a single platform and contract saving over \$700K/year.

Per study costs starting as low as 7 cents.


500,000 studies per year may be archived for \$35K/year. Gain access to an ecosystem of clinical data applications.

Require 67% less time and effort to setup and configure

Delivered a PACS replacement in under 3 months. Deployed and brought live the platform in just over one month.

Require 45% less infrastructure to deploy and operate

Archived over 16 million studies in a single year on a single platform and database running 6 servers.




Meet your data assistant.
#WORKSMART with Sage.



Build Your Healthcare Ecosystem

Complimenting your EMR, leverage Sage to enable EMR interoperability and to extend the capabilities on and beyond the scope of your EMR.



MACH7 – SirenMD PARTNERSHIP

Mach7 and SirenMD have partnered to deliver SirenMD's care coordination capabilities to Mach7's customers.



- SirenMD harnesses the power of the Mach7 Data Services Platform to provide organized aggregated clinical data to a team of providers to coordinate patient care seamlessly.
- Together both our companies provide updates in real-time and access to the latest information about a patients' medical event. We align all members of the care team into one unified care coordination effort.



MACH7 SOLUTIONS

Mach7 solutions are designed for end users to improve patient care. All solutions may be deployed onsite, in the cloud, or through a combination of cloud services and onsite solutions.



Management Studio

Delivers core information technology to better manage and own your data.

Enterprise Imaging Platform	Vendor Neutral Archive (VNA)
Communication Workflow Engine	Routing Engine
Fetching Engine	Migration Engine

Clinical Studio

Provides a zero footprint web based user interface designed for clinical user access, content capture, and sharing.

Clinical Viewer	Referring Physician & Patient Portal
Patient & Order Management	Image Sharing
Care Coordination Powered with 	Clinical Content Capture (iModality)

Diagnostic Studio

Delivers solutions designed for the specialist to deliver better patient results.


PACS Powered with 	Universal Worklist
QC Workflow	Modality Worklist (DMWL)

Analytic Studio

Provides a platform for adopting deep learning technologies while optimising operations today.

Sage AI	Sage Descriptive Analytics
Predictive Analytics Connectors	

STRATEGY TO WIN



MANAGEMENT TEAM



Mike Jackman
CEO

- Experienced HCIT executive
- Formerly Americas Region CEO HCIT at GE Healthcare
- The business leader responsible for the GE Healthcare Digital business in Latin America, US, and Canada.



Jenni Pilcher
CFO

- Executive experience in healthcare
- Former CFO of Alchemia, and CFO and Co-Sec of Mesoblast
- Worked in finance teams at Cadbury and Medeva plc.



Eric Rice
CTO

- 20 years of systems architecture and design, engineering and management experience
- Held leadership roles and designed solutions for GE Healthcare.



Ravi Krishnan
FOUNDER, CSO

- Founding partner of Mach7 Technologies
- Nearly 20 years of experience with technology intricacies that drive medical imaging
- Previously worked at GE Healthcare and Agfa Healthcare.



Mike Lampron
COO

- More than 20 years experience in business and operational management for HCIT companies
- Mike is responsible for our customers' success while driving excellence throughout Mach7.

THANK YOU -
QUESTIONS

